Recent Posts

Merck, Canadian Plaintiffs Settle Vioxx Litigation For Up To $36.3 Million
Posted on 20 Jan 2012 by Tom Moylan

(Mealey's) Merck Sharp & Dohme Corp. and plaintiffs' counsel in four Canadian Vioxx class actions announced Jan. 19 that they have agreed to settle the litigation for up to $36.3 million ( Mignacca, et al. v. Merck Frosst Canada Ltd, et al... Read More

High Court Upholds 3rd Circuit's Ruling, Finds Stockholder's Suit Against Merck Was Timely
Posted on 27 Apr 2010 by Michael Lefkowitz

WASHINGTON, D.C. - (Mealey's) The U.S. Supreme Court on April 27 affirmed a Third Circuit U.S. Court of Appeals ruling that a shareholder derivative lawsuit over Merck & Co. Inc.'s marketing of Vioxx was timely and held that the statute of... Read More

Federal Judge Dismisses Consumer Lawsuit Over Pfizer Drugs
Posted on 21 Jul 2010 by Michael Lefkowitz

PHILADELPHIA - (Mealey's) A federal judge in Pennsylvania on July 20 dismissed a putative consumer class action that alleged fraudulent marketing of 12 Pfizer Inc. drugs, saying that the plaintiffs failed to demonstrate an injury or reliance upon... Read More

Australian Court: Vioxx Doubled Heart Attack Risk
Posted on 8 Mar 2010 by LexisNexis Litigation Resource Community Staff

SYDNEY, Australia – (AP) The once-popular painkiller Vioxx doubled the risk of heart attack and was unfit for consumption, an Australian court ruled Friday, awarding a man leading a class action suit against the drug's maker 287,000 Australian... Read More

Supreme Court Says Vioxx Lawsuit Can Proceed
Posted on 27 Apr 2010 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. – (AP) The Supreme Court said Tuesday investors who lost millions betting on the blockbuster drug Vioxx can sue Merck & Co. over whether the pharmaceutical giant provided enough information about the painkiller's risks before... Read More